Maris-Tech to Report 2023 Financial Results and Present 2024 Forecast on March 26, 2024
March 19, 2024 08:10 ET
|
Maris-Tech Ltd.
The Company will host a webinar with investors on Tuesday, March 26, 2024 at 9:00 a.m., Eastern Time Rehovot, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW)...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
March 19, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
Kering: 2023 Universal Registration Document (URD) available
March 19, 2024 07:38 ET
|
KERING
Press release_2023 Universal Registration Document available_19 03 24 PRESS RELEASE March 19, 2024 2023 UNIVERSAL REGISTRATION DOCUMENT AVAILABLE Kering's 2023 Universal...
Kering : Communiqué de mise à disposition du Document d'enregistrement universel 2023
March 19, 2024 07:38 ET
|
KERING
Communiqué_Mise à disposition du Document d'enregistrement universel 2023_19 03 24 COMMUNIQUÉ DE PRESSE 19 mars 2024 COMMUNIQUÉ DE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL...
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
March 19, 2024 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
Formula Systems Reports Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 07:08 ET
|
Formula Systems (1985) Ltd.
OR YEHUDA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Or Yehuda, Israel, March 19, 2024 – Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information...
TrueContext Reports Annual and Q4 2023 Financial Results
March 19, 2024 07:00 ET
|
TrueContext Corporation
TrueContext announces 15% year-on-year recurring revenue growth and profitability in Q4 2023.
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024 07:00 ET
|
Tourmaline Bio, Inc.
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported...
MAG Silver Reports 2023 Annual Financial Results
March 19, 2024 06:55 ET
|
MAG Silver Corp.
VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces the Company’s consolidated financial results for the...